289 related articles for article (PubMed ID: 28484265)
1. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML
Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
[TBL] [Abstract][Full Text] [Related]
3. JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL.
Benyoucef A; Haigh K; Cuddihy A; Haigh JJ
Leukemia; 2022 Dec; 36(12):2802-2816. PubMed ID: 36229595
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes.
Meyer LK; Huang BJ; Delgado-Martin C; Roy RP; Hechmer A; Wandler AM; Vincent TL; Fortina P; Olshen AB; Wood BL; Horton TM; Shannon KM; Teachey DT; Hermiston ML
J Clin Invest; 2020 Feb; 130(2):863-876. PubMed ID: 31687977
[TBL] [Abstract][Full Text] [Related]
5. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
van der Zwet JCG; Buijs-Gladdines JGCAM; Cordo' V; Debets DO; Smits WK; Chen Z; Dylus J; Zaman GJR; Altelaar M; Oshima K; Bornhauser B; Bourquin JP; Cools J; Ferrando AA; Vormoor J; Pieters R; Vormoor B; Meijerink JPP
Leukemia; 2021 Dec; 35(12):3394-3405. PubMed ID: 34007050
[TBL] [Abstract][Full Text] [Related]
6. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
[TBL] [Abstract][Full Text] [Related]
7. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.
Zhang M; Mathews Griner LA; Ju W; Duveau DY; Guha R; Petrus MN; Wen B; Maeda M; Shinn P; Ferrer M; Conlon KD; Bamford RN; O'Shea JJ; Thomas CJ; Waldmann TA
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12480-5. PubMed ID: 26396258
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
9. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE
Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039
[TBL] [Abstract][Full Text] [Related]
10. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
11. The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
Girardi T; Vereecke S; Sulima SO; Khan Y; Fancello L; Briggs JW; Schwab C; de Beeck JO; Verbeeck J; Royaert J; Geerdens E; Vicente C; Bornschein S; Harrison CJ; Meijerink JP; Cools J; Dinman JD; Kampen KR; De Keersmaecker K
Leukemia; 2018 Mar; 32(3):809-819. PubMed ID: 28744013
[TBL] [Abstract][Full Text] [Related]
12. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.
Sharma ND; Nickl CK; Kang H; Ornatowski W; Brown R; Ness SA; Loh ML; Mullighan CG; Winter SS; Hunger SP; Cannon JL; Matlawska-Wasowska K
Cancer Sci; 2019 Jun; 110(6):1931-1946. PubMed ID: 30974024
[TBL] [Abstract][Full Text] [Related]
14. Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.
Bonaccorso P; Bugarin C; Buracchi C; Fazio G; Biondi A; Lo Nigro L; Gaipa G
Cytometry B Clin Cytom; 2020 Nov; 98(6):491-503. PubMed ID: 32479694
[TBL] [Abstract][Full Text] [Related]
15. Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal.
Xie M; Yang A; Ma J; Wu M; Xu H; Wu K; Jin Y; Xie Y
Cell Death Dis; 2019 Jan; 9(10):1013. PubMed ID: 30598523
[TBL] [Abstract][Full Text] [Related]
16. Low-dose anisomycin sensitizes glucocorticoid-resistant T-acute lymphoblastic leukemia CEM-C1 cells to dexamethasone-induced apoptosis through activation of glucocorticoid receptor and p38-MAPK/JNK.
Liu Y; Ge J; Li Q; Guo X; Gu L; Ma ZG; Li XH; Zhu YP
Leuk Lymphoma; 2014 Sep; 55(9):2179-88. PubMed ID: 24597985
[TBL] [Abstract][Full Text] [Related]
17. IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
Gianfelici V; Messina M; Paoloni F; Peragine N; Lauretti A; Fedullo AL; Di Giacomo F; Vignetti M; Vitale A; Guarini A; Chiaretti S; Foà R
Leuk Lymphoma; 2019 Mar; 60(3):829-832. PubMed ID: 30188230
[No Abstract] [Full Text] [Related]
18. Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia.
Samuels AL; Heng JY; Beesley AH; Kees UR
Br J Haematol; 2014 Apr; 165(1):57-66. PubMed ID: 24456076
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential.
Treanor LM; Zhou S; Janke L; Churchman ML; Ma Z; Lu T; Chen SC; Mullighan CG; Sorrentino BP
J Exp Med; 2014 Apr; 211(4):701-13. PubMed ID: 24687960
[TBL] [Abstract][Full Text] [Related]
20. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
Mohrherr J; Haber M; Breitenecker K; Aigner P; Moritsch S; Voronin V; Eferl R; Moriggl R; Stoiber D; Győrffy B; Brcic L; László V; Döme B; Moldvay J; Dezső K; Bilban M; Popper H; Moll HP; Casanova E
Int J Cancer; 2019 Dec; 145(12):3376-3388. PubMed ID: 31407334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]